Your browser doesn't support javascript.
loading
PD-L2 based immune signature confers poor prognosis in HNSCC.
Qiao, Yu; Liu, Chao; Zhang, Xiaoyue; Zhou, Qianqian; Li, Yatian; Xu, Yini; Gao, Zhenyue; Xu, Yiqi; Kong, Lingping; Yang, Aifeng; Mei, Mei; Ren, Yu; Wang, Xudong; Zhou, Xuan.
Affiliation
  • Qiao Y; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
  • Liu C; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
  • Zhang X; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
  • Zhou Q; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
  • Li Y; Department of Genetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Xu Y; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
  • Gao Z; Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Xu Y; Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Kong L; Department of Oncology, Tianjin Medical University General Hospital, Tianjin, China.
  • Yang A; Department of Second General Surgery, Shuangyashan People's Hospital, Heilongjiang, China.
  • Mei M; Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Ren Y; Department of Genetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Wang X; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
  • Zhou X; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
Oncoimmunology ; 10(1): 1947569, 2021.
Article in En | MEDLINE | ID: mdl-34377590
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Head and Neck Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Head and Neck Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Year: 2021 Type: Article